Drugs Made In America II delays Q3 2025 Form 10-Q filing

Drugs Made In America Acquisition II Corp. filed a Form 12b-25 to notify the SEC that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late.

Rhea-AI Filing Summary

Drugs Made In America Acquisition II Corp. filed a Form 12b-25 to notify the SEC that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company explains that its financial statements could not be completed in time to obtain the required review and signatures before the normal deadline. By using this notification, it indicates that it expects to file the delayed 10-Q within the short extension period permitted under SEC Rule 12b-25.

Insights

Equity analyst

DMIIU reports a short administrative delay in filing its Q3 2025 10-Q.

Drugs Made In America Acquisition II Corp. has notified the SEC via Form 12b-25 that its Form 10-Q for the quarter ended September 30, 2025 will be late. The reason given is that the financial statements were not finished in time to secure all required internal review and signatures before the original due date.

By filing this notice, the company signals that it expects to submit the 10-Q within the limited extension window allowed by Rule 12b-25 for quarterly reports. The explanation focuses on timing and process rather than identifying a specific accounting issue. The practical importance will depend on how quickly the 10-Q is subsequently filed and whether it discloses any operational or financial changes once available.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DMIIU disclose in its Form 12b-25 filing?

Drugs Made In America Acquisition II Corp. disclosed that it will not file its Form 10-Q for the quarter ended September 30, 2025 by the original deadline and is using Form 12b-25 to request a short extension.

Why is DMIIUs Q3 2025 Form 10-Q filing delayed?

The company states that the financial statements for the quarter ended September 30, 2025 could not be completed in sufficient time to obtain the necessary review of the report and signatures before the due date.

How long of an extension does DMIIU seek for its late 10-Q?

By filing Form 12b-25, the company indicates that it expects to file the delayed Form 10-Q within the short extension period allowed under SEC Rule 12b-25 for quarterly reports.

Does the Form 12b-25 say anything about DMIIUs operations or earnings?

The notification explains the timing and process reason for the late Form 10-Q filing but does not itself provide detailed operational or earnings information.

Who signed DMIIUs late-filing notification?

The Form 12b-25 notification was signed on behalf of Drugs Made In America Acquisition II Corp. by Lynn Stockwell, its Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 09:36 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

	NOTIFICATION OF LATE FILING	SEC FILE NUMBER
		001-42863
		CUSIP NUMBER
		G2851K104

(Check One):	☐ Form 10-K	☐ Form 20-F	☐ Form 11-K	☒ Form 10-Q	☐ Form 10-D	☐ Form N-CEN
	☐ Form N-CSR

For Period Ended: September 30, 2025 

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q

For the Transition Period Ended: _______________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

Drugs Made In America Acquisition II Corp.

Full Name of Registrant

Former Name if Applicable

1 East Broward Boulevard, Suite 700

Address of Principal Executive Office (Street and Number)

Fort Lauderdale, FL 33301

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

We could not timely file our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion prior to the due date of the report.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Lynn Stockwell		(954)		870-3099
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).	☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?	☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Drugs Made In America Acquisition II Corp.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date : November 14, 2025	By:	/s/ Lynn Stockwell
		Name:	Lynn Stockwell
		Title:	Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

3